Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Time to improvement 37% Improvement Relative Risk Time to improvement (b) 59% c19early.org/a Shinkai et al. Favipiravir for COVID-19 RCT LATE Is late treatment with favipiravir beneficial for COVID-19? RCT 156 patients in Japan Faster recovery with favipiravir (p=0.014) Shinkai et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4 Favors favipiravir Favors control
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Shinkai et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4
Shinkai et al., Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A.., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4
Aug 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
time to improvement, 37.1% lower, HR 0.63, p = 0.01, treatment 107, control 49, adjusted per study, inverted to make HR<1 favor treatment, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
time to improvement, 58.5% lower, HR 0.41, p = 0.01, treatment 47, control 13, adjusted per study, inverted to make HR<1 favor treatment, <5 days from onset of fever, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shinkai et al., 27 Aug 2021, Single Blind Randomized Controlled Trial, Japan, peer-reviewed, 39 authors, average treatment delay 4.8 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Infect Dis Ther (2021) 10:2489–2509 https://doi.org/10.1007/s40121-021-00517-4 ORIGINAL RESEARCH Efficacy and Safety of Favipiravir in Moderate COVID19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial Masaharu Shinkai . Kenji Tsushima . Shingo Tanaka . Eri Hagiwara . Norihito Tarumoto . Ichiro Kawada . Yuji Hirai . Sho Fujiwara . Yuko Komase . Takeshi Saraya . Hidefumi Koh . Naho Kagiyama . Megumi Shimada . Daiki Kanou . Shinichi Antoku . Yujiro Uchida . Yutaka Tokue . Mikio Takamori . Yasuhiro Gon . Kenya Ie . Yoshitaka Yamazaki . Kazumasa Harada . Naoki Miyao . Takashi Naka . Mitsunaga Iwata . Atsushi Nakagawa . Kazutoshi Hiyama . Yoshihiko Ogawa . Masahiro Shinoda . Shinichiro Ota . Takatomo Hirouchi . Jiro Terada . Shuichi Kawano . Takashi Ogura . Tsutomu Sakurai . Yoshihiko Matsumoto . Hiroyuki Kunishima . Osamu Kobayashi . Satoshi Iwata Received: May 21, 2021 / Accepted: July 27, 2021 / Published online: August 27, 2021 Ó The Author(s) 2021 ABSTRACT Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipi- Supplementary Information The online version contains supplementary material available at https:// doi.org/10.1007/s40121-021-00517-4. ravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit RNA-dependent RNA polymerase. A preliminary trial in COVID-19 patients reported significant improvements across a multitude of clinical parameters, but these findings have not been confirmed in an adequate well-controlled trial. We conducted a randomized, single-blind, placebo-controlled Phase III trial assessing the efficacy and safety of favipiravir in patients with M. Shinkai  M. Shinoda  S. Ota  T. Hirouchi Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawaku, Tokyo 140-8522, Japan N. Tarumoto Department of Infectious Disease and Infection control, Saitama Medical University Hospital, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan K. Tsushima  J. Terada Department of Pulmonary Medicine, School of Medicine, International University of Health and Welfare, 852 Hatakeda, Narita, Chiba 286-8520, Japan I. Kawada Division of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan S. Tanaka Department of Otolaryngology, Self-Defense Forces Central Hospital, 1-2-24 Ikejiri, Setagaya-ku, Tokyo 154-8532, Japan E. Hagiwara  T. Ogura Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama, Kanagawa 236-0051, Japan Y. Hirai Department of Infectious Diseases, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji, Tokyo 193-0998, Japan S. Fujiwara Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan 2490 moderate pneumonia not requiring oxygen therapy. Methods: COVID-19 patients with moderate pneumonia (SpO2 C 94%) within 10 days of onset of fever (temperature C 37.5 °C) were assigned to receive either placebo or favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days) in a ratio of 1:2. An adaptive design was used to re-estimate the sample size. The primary endpoint was a..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit